Filing Flows › Comparisons › JAGX vs ENSC
Jaguar Health vs Ensysce Biosciences: JAGX and ENSC compared
Jaguar Health is the larger company: $1.2M of revenue in its latest quarter (Q2 2026) against $1.2M for Ensysce Biosciences (Q2 2026). Ensysce Biosciences is growing faster (-15% against -59% a year earlier). Ensysce Biosciences is more profitable, with an operating margin of -221.3% against -620.2%.
Where the money goes: JAGX and ENSC
Jaguar Health (JAGX) · Q2 2026
Jaguar Health, Q2 2026: revenue $1.2M (-59% year over year), operating margin -620.2%, net loss $12.8M, operating cash flow −$5.3M. The chart follows the revenue to costs, profit and cash.
Ensysce Biosciences (ENSC) · Q2 2026
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Jaguar Health (JAGX) | Ensysce Biosciences (ENSC) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.2M | $1.2M |
| Revenue growth, Y/Y | -59% | -15% |
| Operating margin | -620.2% | -221.3% |
| Net earnings | −$12.8M | −$2.6M |
| Net margin | — | -220.8% |
| Operating cash flow | −$5.3M | −$2.0M |
Where the revenue comes from
Jaguar Health
- Product: $1.2M (96%)
- License: $43K (4%)
Questions
Which is bigger, Jaguar Health or Ensysce Biosciences?
Jaguar Health is the larger company: $1.2M of revenue in its latest quarter (Q2 2026) against $1.2M for Ensysce Biosciences (Q2 2026).
Is Jaguar Health or Ensysce Biosciences growing faster?
Ensysce Biosciences is growing faster (-15% against -59% a year earlier).
Which is more profitable, Jaguar Health or Ensysce Biosciences?
Ensysce Biosciences is more profitable, with an operating margin of -221.3% against -620.2%.
More: Jaguar Health earnings · how Jaguar Health makes money · Ensysce Biosciences earnings · how Ensysce Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 19, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.